Histological workup revealed an amelanotic melanoma (Figure 3B), which had no evident driver mutation, but mutations in JAK2 and MITF. For the next two years, the patient underwent various treatment lines that were continuously adjusted depending on disease progression monitored by FDG-PET/CT (Figure 3A). This evidence concerns the gene JAK2 and melanoma.